Related Experiment Video
Updated: Jan 8, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Endothelial-specific genes TMTC1, RPS6KA2, and F8 are downregulated in hypertrophic cardiomyopathy
Pingge Tian1, Lei Xu2, Fan Zou3
1Department of Cardiology, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, 510000, China. litianshi840306@163.com.
Insights
This study identifies TMTC1, RPS6KA2, and F8 as key genes involved in hypertrophic cardiomyopathy (HCM) pathogenesis. These genes, particularly TMTC1, show potential for diagnosing and treating endothelial dysfunction in HCM.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Genomics
Background:
- Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease.
- Endothelial cells (ECs) are crucial in HCM pathogenesis, but mechanisms of dysfunction are unclear.
Purpose of the Study:
- To identify molecular mechanisms and biomarkers of endothelial dysfunction in HCM.
- To investigate the role of specific genes and pathways in HCM pathogenesis.
Main Methods:
- Single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing data analysis.
- Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and transcription factor network construction.
- Quantitative real-time PCR (qPCR), CCK-8, and Transwell assays to validate gene function.
Main Results:
- Identified ECs and cardiomyocytes as major cell types in HCM.
- Revealed TGF-β signaling pathway activation and identified key EC transcription factors (NFIB, MECOM, FLI1).
- Discovered TMTC1, RPS6KA2, and F8 as downregulated genes in HCM with high diagnostic efficacy (>0.7 AUC); TMTC1 overexpression reversed Ang II-induced endothelial cell injury.
Conclusions:
- TMTC1, RPS6KA2, and F8 are potential diagnostic biomarkers for HCM.
- Targeting identified pathways and genes may offer new therapeutic strategies for HCM.
- Provides deeper insights into the pathogenesis of endothelial dysfunction in HCM.
Background:
Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease characterized by left ventricular hypertrophy and excessive myocardial contraction. Endothelial cells (ECs) play a key role in the pathogenesis of HCM, and their secreted growth factors regulate the growth and function of cardiomyocytes. However, the specific molecular mechanisms and biomarkers associated with endothelial dysfunction in HCM remain unclear.
Methods:
Single-cell RNA sequencing (scRNA-seq) data were downloaded from the Gene Expression Omnibus (GEO) database (GSE255296), and bulk RNA sequencing data were obtained from GSE249925 and GSE180313. The scRNA-seq data were processed using the Seurat package for cell type annotation and batch effect removal. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis was performed, and pathway activity was evaluated using the AUCell algorithm. SCENIC was applied to construct transcription factor-specific regulatory networks. Differential gene expression analysis was conducted using the limma package, and key genes were determined by intersecting differentially expressed genes (DEGs) with EC-specific highly expressed genes. The diagnostic efficacy of these key genes was assessed via receiver operating characteristic (ROC) curve analysis. The mRNA expression of genes in HUVECs treated with or without angiotensin II (Ang II) was assessed using qPCR. Cell viability was determined using the CCK-8 assay, and cell invasive ability was evaluated through Transwell assays to investigate the regulatory effect of TMTC1 overexpression on Ang II-induced injury in HUVECs.
Results:
Seven major cell types were identified, with cardiomyocytes and ECs being the main cell populations in HCM. KEGG enrichment analysis revealed significant activation of pathways such as the transforming growth factor-beta (TGF-β) signaling pathway in ECs. High-activity transcription factors NFIB, MECOM, and FLI1 were identified in ECs, whose target genes were enriched in processes related to cell morphogenesis. Three key genes-TMTC1, RPS6KA2, and F8-were selected based on differential expression and EC specificity. These genes were lowly expressed in HCM and exhibited high diagnostic efficacy, with area under the curve (AUC) values > 0.7. Ultimately, the CCK-8 assay results indicated that Ang II inhibited the viability of HUVECs, and this inhibitory effect could be reversed by the overexpression of TMTC1 (oe-TMTC1). Furthermore, Transwell assays indicated that Ang II impaired cellular migration, and this impairment could be restored by oe-TMTC1.
Conclusion:
The identified key genes and pathways provide new targets for therapeutic intervention and contribute to a deeper understanding of the pathogenesis of HCM.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Regulation of Angiogenesis and Blood Supply
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy

